snoRNPs regulate telomerase activity in neuroblastoma and are associated with poor prognosis

Translational Oncology

Volumn 6, Issue 4, 2013, Pages 447-457

  von Stedingk, Kristoffer ^a   Koster, Jan ^b   Piqueras, Marta ^c   Noguera, Rosa ^c   Navarro, Samuel ^c   Påhlman, Sven ^a   Versteeg, Rogier ^b   Øra, Ingrid ^c,d   Gisselsson, David ^a   Lindgren, David ^a   Axelson, Håkan ^a  

^a LUND UNIVERSITY   (Sweden)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF VALENCIA   (Spain)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

SMALL INTERFERING RNA; SMALL NUCLEOLAR RIBONUCLEOPROTEIN; TELOMERASE;

ANAPHASE; ARTICLE; CANCER PROGNOSIS; CHROMOSOMAL INSTABILITY; CHROMOSOME ABERRATION; CONTROLLED STUDY; DKC1 GENE; ENZYME ACTIVITY; GAR1 GENE; GENE; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; NEUROBLASTOMA; NHP2 GENE; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; TELOMERIC REPEAT AMPLIFICATION PROTOCOL; TISSUE MICROARRAY;

EID: 84881040690     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.13112     Document Type: Article

References (46)

1. Maris JM, Hogarty MD, Bagatell R, and Cohn SL (2007). Neuroblastoma. Lancet 369, 2106-2120.
2. Vermeulen J, De Preter K, Mestdagh P, Laureys G, Speleman F, and Vandesompele J (2010). Predicting outcomes for children with neuroblastoma. DiscovMed 10, 29-36.
3. Brodeur GM (2003). Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 3, 203-216.
4. Maris JM (2010). Recent advances in neuroblastoma. N Engl J Med 362, 2202-2211.
5. Molenaar JJ, Koster J, Zwijnenburg DA, van Sluis P, Valentijn LJ, van der Ploeg I, Hamdi M, van Nes J, Westerman BA, van Arkel J, et al. (2012). Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes. Nature 483, 589-593.
6. Janoueix-Lerosey I, Schleiermacher G, Michels E, Mosseri V, Ribeiro A, Lequin D, Vermeulen J, Couturier J, Peuchmaur M, Valent A, et al. (2009). Overall genomic pattern is a predictor of outcome in neuroblastoma. J Clin Oncol 27, 1026-1033.
7. de Lange T (2005). Shelterin: the protein complex that shapes and safeguards human telomeres. Genes Dev 19, 2100-2110.
8. McClintock B (1938). The production of homozygous deficient tissues with mutant characteristics by means of the aberrant mitotic behavior of ring-shaped chromosomes. Genetics 23, 315-376.
9. Ulaner GA (2004). Telomere maintenance in clinical medicine. Am J Med 117, 262-269.
10. Lundberg G, Sehic D, Lansberg JK, Ora I, Frigyesi A, Castel V, Navarro S, Piqueras M, Martinsson T, Noguera R, et al. (2011). Alternative lengthening of telomeres-an enhanced chromosomal instability in aggressive non-MYCN amplified and telomere elongated neuroblastomas. Genes Chromosomes Cancer 50, 250-262.
11. Onitake Y, Hiyama E, Kamei N, Yamaoka H, Sueda T, and Hiyama K (2009). Telomere biology in neuroblastoma: telomere binding proteins and alternative strengthening of telomeres. J Pediatr Surg 44, 2258-2266.
12. Cerone MA, Londono-Vallejo JA, and Bacchetti S (2001). Telomere maintenance by telomerase and by recombination can coexist in human cells. Hum Mol Genet 10, 1945-1952.
13. Guiducci C, Cerone MA, and Bacchetti S (2001). Expression of mutant telomerase in immortal telomerase-negative human cells results in cell cycle deregulation, nuclear and chromosomal abnormalities and rapid loss of viability. Oncogene 20, 714-725.
14. Hakin-Smith V, Jellinek DA, Levy D, Carroll T, Teo M, Timperley WR, McKay MJ, Reddel RR, and Royds JA (2003). Alternative lengthening of telomeres and survival in patients with glioblastoma multiforme. Lancet 361, 836-838.
15. Podlevsky JD and Chen JJ (2012). It all comes together at the ends: telomerase structure, function, and biogenesis. Mutat Res 730, 3-11.
16. Venteicher AS, Meng Z, Mason PJ, Veenstra TD, and Artandi SE (2008). Identification of ATPases pontin and reptin as telomerase components essential for holoenzyme assembly. Cell 132, 945-957.
17. Kiss T, Fayet-Lebaron E, and Jady BE (2010). Box H/ACA small ribonucleo-proteins. Mol Cell 37, 597-606.
18. Ohali A, Avigad S, Ash S, Goshen Y, Luria D, Feinmesser M, Zaizov R, and Yaniv I (2006). Telomere length is a prognostic factor in neuroblastoma. Cancer 107, 1391-1399.
19. Greenberg RA, O'Hagan RC, Deng H, Xiao Q, Hann SR, Adams RR, Lichtsteiner S, Chin L, Morin GB, and DePinho RA (1999). Telomerase reverse transcriptase gene is a direct target of c-Myc but is not functionally equivalent in cellular transformation. Oncogene 18, 1219-1226.
20. Wu KJ, Grandori C, Amacker M, Simon-Vermot N, Polack A, Lingner J, and Dalla-Favera R (1999). Direct activation of TERT transcription by c-MYC. Nat Genet 21, 220-224.
21. Xu D, Popov N, Hou M, Wang Q, Bjorkholm M, Gruber A, Menkel AR, and Henriksson M (2001). Switch from Myc/Max to Mad1/Max binding and decrease in histone acetylation at the telomerase reverse transcriptase promoter during differentiation of HL60 cells. Proc Natl Acad Sci USA 98, 3826-3831.
22. Oberthuer A, Berthold F, Warnat P, Hero B, Kahlert Y, Spitz R, Ernestus K, Konig R, Haas S, Eils R, et al. (2006). Customized oligonucleotide micro-array gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification. J Clin Oncol 24, 5070-5078.
23. Huang da W, Sherman BT, and Lempicki RA (2009). Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4, 44-57.
24. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, and Speleman F (2002). Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3, RESEARCH0034.
25. Darzacq X, Kittur N, Roy S, Shav-Tal Y, Singer RH, and Meier UT (2006). Stepwise RNP assembly at the site of H/ACA RNA transcription in human cells. J Cell Biol 173, 207-218.
26. Pogacic V, Dragon F, and Filipowicz W (2000). Human H/ACA small nucle-olar RNPs and telomerase share evolutionarily conserved proteins NHP2 and NOP10. Mol Cell Biol 20, 9028-9040.
27. Hoareau-Aveilla C, Bonoli M, Caizergues-Ferrer M, and Henry Y (2006). HNaf1 is required for accumulation of human box H/ACA snoRNPs, scaRNPs, and telomerase. RNA 12, 832-840.
28. Grozdanov PN, Roy S, Kittur N, and Meier UT (2009). SHQ1 is required prior to NAF1 for assembly of H/ACA small nucleolar and telomerase RNPs. RNA 15, 1188-1197.
29. Fredlund E, Ringner M, Maris JM, and Pahlman S (2008). High Myc pathway activity and low stage of neuronal differentiation associate with poor outcome in neuroblastoma. Proc Natl Acad Sci USA 105, 14094-14099.
30. Chan SR and Blackburn EH (2004). Telomeres and telomerase. Philos Trans R Soc Lond B Biol Sci 359, 109-121.
31. Gisselsson D (2005). Mitotic instability in cancer: is there method in the madness? Cell Cycle 4, 1007-1010.
32. Schvartzman JM, Sotillo R, and Benezra R (2010). Mitotic chromosomal instability and cancer: mouse modelling of the human disease. Nat Rev Cancer 10, 102-115.
33. De Preter K, Vermeulen J, Brors B, Delattre O, Eggert A, Fischer M, Janoueix-Lerosey I, Lavarino C, Maris JM, Mora J, et al. (2010). Accurate outcome prediction in neuroblastoma across independent data sets using a multigene signature. Clin Cancer Res 16, 1532-1541.
34. Asgharzadeh S, Pique-Regi R, Sposto R, Wang H, Yang Y, Shimada H, Matthay K, Buckley J, Ortega A, and Seeger RC (2006). Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification. J Natl Cancer Inst 98, 1193-1203.
35. Oberthuer A, Hero B, Berthold F, Juraeva D, Faldum A, Kahlert Y, Asgharzadeh S, Seeger R, Scaruffi P, Tonini GP, et al. (2010). Prognostic impact of gene expression-based classification for neuroblastoma. J Clin Oncol 28, 3506-3515.
36. Vermeulen J, De Preter K, Naranjo A, Vercruysse L, Van Roy N, Hellemans J, Swerts K, Bravo S, Scaruffi P, Tonini GP, et al. (2009). Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study. Lancet Oncol 10, 663-671.
37. Fischer M, Oberthuer A, Brors B, Kahlert Y, Skowron M, Voth H, Warnat P, Ernestus K, Hero B, and Berthold F (2006). Differential expression of neuronal genes defines subtypes of disseminated neuroblastoma with favorable and unfavorable outcome. Clin Cancer Res 12, 5118-5128.
38. Schramm A, Schulte JH, Klein-Hitpass L, Havers W, Sieverts H, Berwanger B, Christiansen H, Warnat P, Brors B, Eils J, et al. (2005). Prediction of clinical outcome and biological characterization of neuroblastoma by expression profiling. Oncogene 24, 7902-7912.
39. Wei JS, Greer BT, Westermann F, Steinberg SM, Son CG, Chen QR, Whiteford CC, Bilke S, Krasnoselsky AL, Cenacchi N, et al. (2004). Prediction of clinical outcome using gene expression profiling and artificial neural networks for patients with neuroblastoma. Cancer Res 64, 6883-6891.
40. Garcia I, Mayol G, Rios J, Domenech G, Cheung NK, Oberthuer A, Fischer M, Maris JM, Brodeur GM, Hero B, et al. (2012). A three-gene expression signature model for risk stratification of patients with neuroblastoma. Clin Cancer Res 18, 2012-2023.
41. Ding Z, Wu CJ, Jaskelioff M, Ivanova E, Kost-Alimova M, Protopopov A, Chu GC, Wang G, Lu X, Labrot ES, et al. (2012). Telomerase reactivation following telomere dysfunction yields murine prostate tumors with bone metastases. Cell 148, 896-907.
42. Hu J, Hwang SS, Liesa M, Gan B, Sahin E, Jaskelioff M, Ding Z, Ying H, Boutin AT, Zhang H, et al. (2012). Antitelomerase therapy provokes ALT and mitochondrial adaptive mechanisms in cancer. Cell 148, 651-663.
43. Savage SA and Bertuch AA (2010). The genetics and clinical manifestations of telomere biology disorders. Genet Med 12, 753-764.
44. Sieron P, Hader C, Hatina J, Engers R, Wlazlinski A, Muller M, and Schulz WA (2009). DKC1 overexpression associated with prostate cancer progression. Br J Cancer 101, 1410-1416.
45. Montanaro L, Brigotti M, Clohessy J, Barbieri S, Ceccarelli C, Santini D, Taffurelli M, Calienni M, Teruya-Feldstein J, Trere D, et al. (2006). Dyskerin expression influences the level of ribosomal RNA pseudo-uridylation and telo-merase RNA component in human breast cancer. J Pathol 210, 10-18.
46. Turano M, Angrisani A, De Rosa M, Izzo P, and Furia M (2008). Real-time PCR quantification of human DKC1 expression in colorectal cancer. Acta Oncol 47, 1598-1599.